First Defense Technology® Field Demonstration Summary of a field demonstration to evaluate the impact of a First Defense Technology® hyperimmune E/C colostrum powder on calf health.
Sunday, June 7, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: A large-scale calf ranch in the southwestern U.S. conducted a field demonstration to assess the effects of First Defense Technology's hyperimmune E/C colostrum powder on calf health. The study involved around 70 calves daily from various sources, focusing on metrics such as death loss and treatment events. This evaluation aims to enhance calf health management practices.
Price reaction · baseline $9.61 (2026-06-05 close) · 1 other ICCC headline(s) in the window, move may be shared
day 0 close · peak
+0.9%
Market Sentiment Analysis
POSITIVE FACTORS
Successful evaluation of a new health technology for calves.
Involvement of a large-scale ranch indicates significant interest.
Potential for improved calf health through hyperimmune colostrum.
Full Press Release Details
A large-scale calf ranch in the southwestern United States conducted a field demonstration to evaluate the impact of a First Defense Technology hyperimmune E/C colostrum powder on calf health. Hyperimmune E/C colostrum powder is derived from cows hyperimmunized to both E. coli and bovine coronavirus.
The demonstration involved approximately 70 4-day old calves per day from 35 sources with average transit time to the ranch of 20 hours. Researchers tracked death loss, total treatments, first treatment event, and secondary treatment event.
Frequently Asked Questions
What is First Defense Technology?
First Defense Technology involves hyperimmune E/C colostrum powder aimed at improving calf health.
How many calves were involved in the demonstration?
Approximately 70 calves were evaluated daily during the field demonstration.
What diseases does the colostrum target?
The hyperimmune colostrum powder targets E. coli and bovine coronavirus.
What metrics were tracked in the study?
Researchers tracked death loss, total treatments, and treatment events.